You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNilotinib
Accession NumberDB04868
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. [Wikipedia]
Structure
Thumb
Synonyms
Nilotinibum
External Identifiers
  • AMN 107
  • AMN-107
  • AMN107
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
Tasignacapsule200 mg/1oralNovartis Pharmaceuticals Corporation2007-10-29Not applicableUs
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard150 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
Tasignacapsule150 mg/1oralNovartis Pharmaceuticals Corporation2007-10-29Not applicableUs
TasignaCapsule, hard150 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard150 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard150 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
Tasignacapsule200 mgoralNovartis Pharmaceuticals Canada Inc2008-09-30Not applicableCanada
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard150 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
Tasignacapsule150 mgoralNovartis Pharmaceuticals Canada Inc2011-07-15Not applicableCanada
TasignaCapsule, hard200 mgOral useNovartis Europharm Ltd2007-11-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nilotinib hydrochloride monohydrate
ThumbNot applicableDBSALT001325
Categories
UNIIF41401512X
CAS number641571-10-0
WeightAverage: 529.5158
Monoisotopic: 529.183792976
Chemical FormulaC28H22F3N7O
InChI KeyInChIKey=HHZIURLSWUIHRB-UHFFFAOYSA-N
InChI
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
IUPAC Name
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide
SMILES
CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • Pyridinylpyrimidine
  • 1-phenylimidazole
  • N-arylamide
  • Aminobenzoic acid or derivatives
  • Benzoic acid or derivatives
  • Aminotoluene
  • Benzoyl
  • Toluene
  • Pyrimidine
  • Pyridine
  • N-substituted imidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
PharmacodynamicsNilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Mechanism of actionChronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. Nilotinib fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib, over-riding resistance caused by mutations. The ability of AMN107 to inhibit TEL-platelet-derived growth factor receptor-beta (TEL-PDGFRbeta), which causes chronic myelomonocytic leukaemia, and FIP1-like-1-PDGFRalpha, which causes hypereosinophilic syndrome, suggests potential use of AMN107 for myeloproliferative diseases characterised by these kinase fusions (Stover et al, 2005; Weisberg et al, 2005). AMN107 also inhibits the c-Kit receptor kinase, including the D816V-mutated variant of KIT, at pharmacologically achievable concentrations, supporting potential utility in the treatment of mastocytosis, and gastrointestinal stromal tumours (Weisberg et al, 2005; von Bubnoff et al, 2005; Gleixner et al, 2006).
Related Articles
AbsorptionOrally available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life15 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9066
Caco-2 permeable-0.5792
P-glycoprotein substrateNon-substrate0.6879
P-glycoprotein inhibitor IInhibitor0.556
P-glycoprotein inhibitor IIInhibitor0.6002
Renal organic cation transporterNon-inhibitor0.8253
CYP450 2C9 substrateNon-substrate0.8178
CYP450 2D6 substrateNon-substrate0.8547
CYP450 3A4 substrateSubstrate0.5552
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.5739
CYP450 2D6 inhibitorNon-inhibitor0.8275
CYP450 2C19 inhibitorInhibitor0.5554
CYP450 3A4 inhibitorInhibitor0.6784
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7862
Ames testNon AMES toxic0.5204
CarcinogenicityNon-carcinogens0.8175
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6343 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Inhibitor0.8458
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral150 mg
Capsuleoral150 mg/1
Capsuleoral200 mg/1
Capsuleoral200 mg
Capsule, hardOral use150 mg
Capsule, hardOral use200 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2491632 No2009-11-102023-07-04Canada
US7169791 No2003-07-042023-07-04Us
US8163904 No2008-08-232028-08-23Us
US8293756 No2007-09-252027-09-25Us
US8389537 No2006-07-182026-07-18Us
US8415363 No2006-07-182026-07-18Us
US8501760 No2006-07-182026-07-18Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00201 mg/mLALOGPS
logP4.51ALOGPS
logP4.41ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.86ChemAxon
pKa (Strongest Basic)6.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.62 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity152.85 m3·mol-1ChemAxon
Polarizability52.35 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yanling WANG, Jie LI, Vinod Kumar KANSAL, Jirang ZHU, Revital LIFSHITZ-LIRON, Dhirenkumar N. MISTRY, Sanjay L. VASOYA, Sundaraselvan ARIYAMUTHU, Gideon PILARSKI, Xungui HE, “NILOTINIB INTERMEDIATES AND PREPARATION THEREOF.” U.S. Patent US20100016590, issued January 21, 2010.

US20100016590
General References
  1. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [PubMed:16775235 ]
  2. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. [PubMed:17929114 ]
  3. Breccia M, Cannella L, Nanni M, Stefanizzi C, Alimena G: Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol. 2007;118(3):162-4. Epub 2007 Sep 20. [PubMed:17890849 ]
  4. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [PubMed:17715389 ]
  5. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H: Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007 Jul;10(7):468-79. [PubMed:17642017 ]
External Links
ATC CodesL01XE08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (68.9 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nilotinib.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Nilotinib.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Nilotinib.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nilotinib.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nilotinib.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nilotinib.
AcetaminophenThe serum concentration of Nilotinib can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nilotinib.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Nilotinib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Nilotinib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nilotinib.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nilotinib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nilotinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Nilotinib.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Nilotinib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Nilotinib.
AlbendazoleThe serum concentration of Nilotinib can be increased when it is combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Nilotinib.
AldosteroneThe serum concentration of Nilotinib can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nilotinib.
AlectinibThe serum concentration of Nilotinib can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Nilotinib.
AlfentanilThe serum concentration of Nilotinib can be increased when it is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Nilotinib.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Nilotinib.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Nilotinib.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nilotinib.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Nilotinib.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nilotinib.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nilotinib.
AlosetronThe metabolism of Alosetron can be decreased when combined with Nilotinib.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nilotinib.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Nilotinib.
Aluminum hydroxideThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum phosphate.
AmantadineThe serum concentration of Nilotinib can be increased when it is combined with Amantadine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Nilotinib.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Nilotinib.
Aminohippuric acidThe serum concentration of Nilotinib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nilotinib.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Nilotinib.
AmiodaroneThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.
AmiodaroneNilotinib may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Nilotinib.
AmitriptylineThe serum concentration of Nilotinib can be increased when it is combined with Amitriptyline.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Nilotinib.
AmlodipineThe serum concentration of Nilotinib can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nilotinib.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Nilotinib.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Nilotinib.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Nilotinib.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nilotinib.
AmprenavirThe serum concentration of Nilotinib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Nilotinib can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Nilotinib.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Nilotinib.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nilotinib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nilotinib.
ApomorphineApomorphine may increase the QTc-prolonging activities of Nilotinib.
ApremilastThe metabolism of Apremilast can be decreased when combined with Nilotinib.
AprepitantThe serum concentration of Nilotinib can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Nilotinib.
AprindineThe metabolism of Aprindine can be decreased when combined with Nilotinib.
ArformoterolArformoterol may increase the QTc-prolonging activities of Nilotinib.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Nilotinib.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Nilotinib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Nilotinib.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Nilotinib.
ArtemetherNilotinib may increase the QTc-prolonging activities of Artemether.
AsenapineNilotinib may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Nilotinib.
AstemizoleThe serum concentration of Nilotinib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Nilotinib can be increased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Nilotinib.
AtenololThe serum concentration of Nilotinib can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Nilotinib can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Nilotinib.
AtorvastatinThe serum concentration of Nilotinib can be increased when it is combined with Atorvastatin.
AvanafilThe metabolism of Avanafil can be decreased when combined with Nilotinib.
AxitinibThe metabolism of Axitinib can be decreased when combined with Nilotinib.
AzelastineThe metabolism of Azelastine can be decreased when combined with Nilotinib.
AzelastineThe serum concentration of Nilotinib can be increased when it is combined with Azelastine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Nilotinib.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Nilotinib.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Nilotinib.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Nilotinib.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Nilotinib.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Nilotinib.
BenzocaineThe serum concentration of Nilotinib can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Nilotinib.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nilotinib.
BepridilThe serum concentration of Nilotinib can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Nilotinib.
BeraprostThe metabolism of Beraprost can be decreased when combined with Nilotinib.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nilotinib.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Nilotinib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Nilotinib.
BexaroteneThe serum concentration of Nilotinib can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nilotinib.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Nilotinib.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Nilotinib.
BiperidenThe serum concentration of Nilotinib can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe serum concentration of Nilotinib can be decreased when it is combined with Bismuth Subcitrate.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Nilotinib.
BoceprevirThe serum concentration of Nilotinib can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Nilotinib.
BortezomibThe metabolism of Nilotinib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nilotinib can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nilotinib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nilotinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nilotinib.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Nilotinib.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nilotinib.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Nilotinib.
BromocriptineThe serum concentration of Nilotinib can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nilotinib.
BudesonideThe metabolism of Budesonide can be decreased when combined with Nilotinib.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Nilotinib.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Nilotinib.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nilotinib.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nilotinib.
BuprenorphineThe serum concentration of Nilotinib can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Nilotinib.
BuserelinBuserelin may increase the QTc-prolonging activities of Nilotinib.
BuspironeThe metabolism of Buspirone can be decreased when combined with Nilotinib.
BuspironeThe serum concentration of Nilotinib can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Nilotinib.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Nilotinib.
CabazitaxelThe serum concentration of Nilotinib can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Nilotinib.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nilotinib.
CaffeineThe metabolism of Caffeine can be decreased when combined with Nilotinib.
CaffeineThe serum concentration of Nilotinib can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Nilotinib.
Calcium carbonateThe serum concentration of Nilotinib can be decreased when it is combined with Calcium carbonate.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nilotinib.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nilotinib.
CanagliflozinThe serum concentration of Nilotinib can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Nilotinib can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Nilotinib can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Nilotinib.
CarbamazepineThe serum concentration of Nilotinib can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Nilotinib.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nilotinib.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nilotinib.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nilotinib.
CarteololThe metabolism of Carteolol can be decreased when combined with Nilotinib.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Nilotinib.
CarvedilolThe serum concentration of Nilotinib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Nilotinib can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nilotinib.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nilotinib.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Nilotinib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nilotinib.
CeritinibThe serum concentration of Nilotinib can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Nilotinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nilotinib.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Nilotinib.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nilotinib.
ChloroquineChloroquine may increase the QTc-prolonging activities of Nilotinib.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Nilotinib.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nilotinib.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Nilotinib.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Nilotinib.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Nilotinib.
ChlorpropamideThe serum concentration of Nilotinib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Nilotinib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nilotinib.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Nilotinib.
CholesterolThe serum concentration of Nilotinib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Nilotinib can be decreased when it is combined with Cholic Acid.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Nilotinib.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nilotinib.
CilazaprilThe serum concentration of Nilotinib can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Nilotinib.
CimetidineThe serum concentration of Nilotinib can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Nilotinib.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Nilotinib.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nilotinib.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Nilotinib.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nilotinib.
CisaprideCisapride may increase the QTc-prolonging activities of Nilotinib.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nilotinib.
CitalopramCitalopram may increase the QTc-prolonging activities of Nilotinib.
ClarithromycinThe serum concentration of Nilotinib can be increased when it is combined with Clarithromycin.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Nilotinib.
ClemastineThe metabolism of Nilotinib can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Nilotinib.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Nilotinib.
ClobazamThe metabolism of Clobazam can be decreased when combined with Nilotinib.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Nilotinib.
ClofazimineThe serum concentration of Nilotinib can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Nilotinib.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nilotinib.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nilotinib.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Nilotinib.
ClomipramineThe serum concentration of Nilotinib can be increased when it is combined with Clomipramine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Nilotinib.
ClonidineThe metabolism of Clonidine can be decreased when combined with Nilotinib.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Nilotinib.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Nilotinib.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nilotinib.
ClotrimazoleThe metabolism of Nilotinib can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Clozapine.
ClozapineClozapine may increase the QTc-prolonging activities of Nilotinib.
CobicistatThe serum concentration of Nilotinib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nilotinib.
CocaineThe metabolism of Cocaine can be decreased when combined with Nilotinib.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nilotinib.
ColchicineThe metabolism of Colchicine can be decreased when combined with Nilotinib.
ColchicineThe serum concentration of Nilotinib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Nilotinib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Nilotinib can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Nilotinib.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Nilotinib.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Nilotinib.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Nilotinib.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Nilotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Nilotinib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nilotinib.
CyclosporineThe metabolism of Nilotinib can be decreased when combined with Cyclosporine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Nilotinib.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nilotinib.
DabrafenibThe serum concentration of Nilotinib can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Nilotinib.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Nilotinib.
DaclatasvirThe serum concentration of Nilotinib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Nilotinib can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Nilotinib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Nilotinib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Nilotinib.
DapsoneThe metabolism of Dapsone can be decreased when combined with Nilotinib.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Nilotinib.
DarunavirThe serum concentration of Nilotinib can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Nilotinib.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nilotinib.
DasatinibThe serum concentration of Nilotinib can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Nilotinib.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Nilotinib.
DaunorubicinThe serum concentration of Nilotinib can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nilotinib.
DeferasiroxThe serum concentration of Nilotinib can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Nilotinib.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Nilotinib.
DelavirdineThe metabolism of Nilotinib can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Nilotinib.
DesfluraneDesflurane may increase the QTc-prolonging activities of Nilotinib.
DesipramineThe serum concentration of Nilotinib can be increased when it is combined with Desipramine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Nilotinib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Nilotinib.
DesloratadineThe serum concentration of Nilotinib can be increased when it is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.
DexamethasoneThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Nilotinib.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Nilotinib.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Nilotinib.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Nilotinib.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nilotinib.
DextromethorphanThe serum concentration of Nilotinib can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Nilotinib.
DiazepamThe metabolism of Diazepam can be decreased when combined with Nilotinib.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nilotinib.
DiclofenacThe serum concentration of Nilotinib can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nilotinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Nilotinib.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Nilotinib.
DigoxinDigoxin may decrease the cardiotoxic activities of Nilotinib.
DigoxinThe metabolism of Digoxin can be decreased when combined with Nilotinib.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nilotinib.
DihydroergotamineThe metabolism of Nilotinib can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nilotinib.
DiltiazemThe metabolism of Nilotinib can be decreased when combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Nilotinib.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Nilotinib.
DipyridamoleThe serum concentration of Nilotinib can be increased when it is combined with Dipyridamole.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Nilotinib.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Nilotinib.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Nilotinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.
DofetilideDofetilide may increase the QTc-prolonging activities of Nilotinib.
DolasetronDolasetron may increase the QTc-prolonging activities of Nilotinib.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Nilotinib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nilotinib.
DomperidoneDomperidone may increase the QTc-prolonging activities of Nilotinib.
DonepezilThe metabolism of Donepezil can be decreased when combined with Nilotinib.
DopamineThe metabolism of Dopamine can be decreased when combined with Nilotinib.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nilotinib.
DoxazosinThe serum concentration of Nilotinib can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Nilotinib.
DoxepinThe metabolism of Doxepin can be decreased when combined with Nilotinib.
DoxepinThe serum concentration of Nilotinib can be increased when it is combined with Doxepin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Nilotinib.
DoxorubicinThe serum concentration of Nilotinib can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Nilotinib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nilotinib.
DronedaroneDronedarone may increase the QTc-prolonging activities of Nilotinib.
DroperidolDroperidol may increase the QTc-prolonging activities of Nilotinib.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nilotinib.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Nilotinib.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Nilotinib.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nilotinib.
EfavirenzThe serum concentration of Nilotinib can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Nilotinib.
ElbasvirThe serum concentration of Nilotinib can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Nilotinib.
EliglustatNilotinib may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe serum concentration of Nilotinib can be increased when it is combined with Eltrombopag.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Nilotinib.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Nilotinib.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Nilotinib.
EnalaprilThe serum concentration of Nilotinib can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Nilotinib.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Nilotinib.
EnzalutamideThe serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Nilotinib.
EpinastineThe serum concentration of Nilotinib can be decreased when it is combined with Epinastine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Nilotinib.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Nilotinib.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Nilotinib.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Nilotinib.
ErgonovineThe serum concentration of Nilotinib can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Nilotinib.
ErgotamineThe serum concentration of Nilotinib can be increased when it is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Nilotinib.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Nilotinib.
ErythromycinErythromycin may increase the QTc-prolonging activities of Nilotinib.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Nilotinib.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Nilotinib.
Eslicarbazepine acetateThe serum concentration of Nilotinib can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Nilotinib.
EsomeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Esomeprazole.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Nilotinib.
EstazolamThe metabolism of Estazolam can be decreased when combined with Nilotinib.
EstradiolThe metabolism of Estradiol can be decreased when combined with Nilotinib.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Nilotinib.
EstramustineThe metabolism of Estramustine can be decreased when combined with Nilotinib.
EstramustineThe serum concentration of Nilotinib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Nilotinib can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Nilotinib.
EstroneThe metabolism of Estrone can be decreased when combined with Nilotinib.
EstroneThe serum concentration of Nilotinib can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Nilotinib.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nilotinib.
EthanolThe metabolism of Ethanol can be decreased when combined with Nilotinib.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Nilotinib.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nilotinib.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Nilotinib.
EtoposideThe metabolism of Etoposide can be decreased when combined with Nilotinib.
EtoposideThe serum concentration of Nilotinib can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nilotinib.
EtravirineThe serum concentration of Nilotinib can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Nilotinib.
EverolimusThe metabolism of Everolimus can be decreased when combined with Nilotinib.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Nilotinib.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Nilotinib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nilotinib.
EzogabineEzogabine may increase the QTc-prolonging activities of Nilotinib.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Nilotinib.
FamotidineThe serum concentration of Nilotinib can be decreased when it is combined with Famotidine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Nilotinib.
FelbamateFelbamate may increase the QTc-prolonging activities of Nilotinib.
FelodipineThe metabolism of Felodipine can be decreased when combined with Nilotinib.
FelodipineThe serum concentration of Nilotinib can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Nilotinib.
FentanylThe metabolism of Fentanyl can be decreased when combined with Nilotinib.
FentanylThe serum concentration of Nilotinib can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.
FexofenadineThe serum concentration of Nilotinib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nilotinib.
FinasterideThe metabolism of Finasteride can be decreased when combined with Nilotinib.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Nilotinib.
FingolimodFingolimod may increase the QTc-prolonging activities of Nilotinib.
FlecainideFlecainide may increase the QTc-prolonging activities of Nilotinib.
FlecainideThe metabolism of Flecainide can be decreased when combined with Nilotinib.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nilotinib.
FluconazoleThe metabolism of Nilotinib can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Nilotinib.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Nilotinib.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nilotinib.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Nilotinib.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Nilotinib.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Nilotinib.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Nilotinib.
FluphenazineThe serum concentration of Nilotinib can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Nilotinib.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Nilotinib.
FlurazepamThe serum concentration of Nilotinib can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Nilotinib.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Nilotinib.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Nilotinib.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nilotinib.
FluvoxamineThe metabolism of Nilotinib can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Nilotinib.
FormoterolThe metabolism of Formoterol can be decreased when combined with Nilotinib.
FosamprenavirThe metabolism of Nilotinib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nilotinib can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Nilotinib.
FosphenytoinThe serum concentration of Nilotinib can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Nilotinib.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Nilotinib.
Fusidic AcidThe serum concentration of Nilotinib can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Nilotinib.
GalantamineThe metabolism of Galantamine can be decreased when combined with Nilotinib.
GalantamineGalantamine may increase the QTc-prolonging activities of Nilotinib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Nilotinib.
GefitinibThe serum concentration of Nilotinib can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nilotinib.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Nilotinib.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Nilotinib.
GenisteinThe serum concentration of Nilotinib can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Nilotinib.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Nilotinib.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Nilotinib.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Nilotinib.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nilotinib.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Nilotinib.
GlyburideThe serum concentration of Nilotinib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Nilotinib can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Nilotinib.
Gramicidin DThe serum concentration of Nilotinib can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Nilotinib.
GranisetronThe metabolism of Granisetron can be decreased when combined with Nilotinib.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nilotinib.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Nilotinib.
GrepafloxacinThe serum concentration of Nilotinib can be increased when it is combined with Grepafloxacin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Nilotinib.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Nilotinib.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Nilotinib.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Nilotinib.
HalothaneThe metabolism of Halothane can be decreased when combined with Nilotinib.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nilotinib.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Nilotinib.
HistrelinHistrelin may increase the QTc-prolonging activities of Nilotinib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Nilotinib.
HydrocortisoneThe serum concentration of Nilotinib can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nilotinib.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nilotinib.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Nilotinib.
IbandronateIbandronate may increase the QTc-prolonging activities of Nilotinib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nilotinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nilotinib.
IbutilideIbutilide may increase the QTc-prolonging activities of Nilotinib.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nilotinib.
IdelalisibThe serum concentration of Nilotinib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nilotinib resulting in a loss in efficacy.
IloperidoneNilotinib may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nilotinib.
ImatinibThe metabolism of Nilotinib can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Nilotinib.
ImipramineThe serum concentration of Nilotinib can be increased when it is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Nilotinib.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Nilotinib.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Nilotinib.
IndapamideThe metabolism of Indapamide can be decreased when combined with Nilotinib.
IndapamideIndapamide may increase the QTc-prolonging activities of Nilotinib.
IndinavirThe serum concentration of Nilotinib can be increased when it is combined with Indinavir.
IndinavirThe metabolism of Indinavir can be decreased when combined with Nilotinib.
IndomethacinThe serum concentration of Nilotinib can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nilotinib.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nilotinib.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nilotinib.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nilotinib.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nilotinib.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nilotinib.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Nilotinib.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nilotinib.
IsavuconazoniumThe metabolism of Nilotinib can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Nilotinib.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nilotinib.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nilotinib.
IsradipineThe metabolism of Nilotinib can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Nilotinib can be increased when it is combined with Itraconazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Nilotinib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Nilotinib.
IvabradineIvabradine may increase the QTc-prolonging activities of Nilotinib.
IvacaftorThe serum concentration of Nilotinib can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Nilotinib.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Nilotinib.
IvermectinThe serum concentration of Nilotinib can be increased when it is combined with Ivermectin.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Nilotinib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nilotinib.
KetamineThe metabolism of Ketamine can be decreased when combined with Nilotinib.
KetamineThe serum concentration of Nilotinib can be increased when it is combined with Ketamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Nilotinib.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nilotinib.
KetoconazoleThe serum concentration of Nilotinib can be increased when it is combined with Ketoconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Nilotinib.
LabetalolThe metabolism of Labetalol can be decreased when combined with Nilotinib.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nilotinib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nilotinib.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Nilotinib.
LansoprazoleThe serum concentration of Nilotinib can be increased when it is combined with Lansoprazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Nilotinib.
LapatinibThe serum concentration of Nilotinib can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Nilotinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nilotinib.
LeflunomideThe risk or severity of adverse effects can be increased when Nilotinib is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nilotinib.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Nilotinib.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Nilotinib.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Nilotinib.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Nilotinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Nilotinib.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nilotinib.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Nilotinib.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Nilotinib.
LevodopaThe metabolism of Levodopa can be decreased when combined with Nilotinib.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Nilotinib.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nilotinib.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Nilotinib.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Nilotinib.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Nilotinib.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Nilotinib.
LevothyroxineThe serum concentration of Nilotinib can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nilotinib.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nilotinib.
LidocaineThe serum concentration of Nilotinib can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Nilotinib.
LiothyronineThe serum concentration of Nilotinib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Nilotinib can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Nilotinib.
LisinoprilThe serum concentration of Nilotinib can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Nilotinib.
LithiumLithium may increase the QTc-prolonging activities of Nilotinib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nilotinib.
LomustineThe metabolism of Lomustine can be decreased when combined with Nilotinib.
LoperamideThe metabolism of Loperamide can be decreased when combined with Nilotinib.
LoperamideThe serum concentration of Nilotinib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Nilotinib can be increased when it is combined with Lopinavir.
LopinavirNilotinib may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Nilotinib.
LoratadineThe serum concentration of Nilotinib can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nilotinib.
LosartanThe metabolism of Losartan can be decreased when combined with Nilotinib.
LosartanThe serum concentration of Nilotinib can be increased when it is combined with Losartan.
LovastatinThe metabolism of Nilotinib can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Nilotinib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Nilotinib can be decreased when it is combined with Lumacaftor.
LumefantrineNilotinib may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Nilotinib.
MacitentanThe metabolism of Macitentan can be decreased when combined with Nilotinib.
MagaldrateThe serum concentration of Nilotinib can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.
Magnesium TrisilicateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium Trisilicate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Nilotinib.
MaprotilineThe serum concentration of Nilotinib can be increased when it is combined with Maprotiline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Nilotinib.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Nilotinib.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Nilotinib.
MebendazoleThe serum concentration of Nilotinib can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nilotinib.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Nilotinib.
MefloquineThe serum concentration of Nilotinib can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Nilotinib can be increased when it is combined with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nilotinib.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nilotinib.
MeprobamateThe serum concentration of Nilotinib can be increased when it is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Nilotinib.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Nilotinib.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Nilotinib.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.
MethadoneMethadone may increase the QTc-prolonging activities of Nilotinib.
MethadoneThe metabolism of Methadone can be decreased when combined with Nilotinib.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Nilotinib.
MethanthelineThe serum concentration of Nilotinib can be decreased when it is combined with Methantheline.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Nilotinib.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nilotinib.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Nilotinib.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Nilotinib.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Nilotinib.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nilotinib.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Nilotinib.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Nilotinib.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Nilotinib.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Nilotinib.
MetiamideThe serum concentration of Nilotinib can be decreased when it is combined with Metiamide.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Nilotinib.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Nilotinib.
MetoprololThe serum concentration of Nilotinib can be increased when it is combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nilotinib.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Nilotinib.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nilotinib.
MianserinThe metabolism of Mianserin can be decreased when combined with Nilotinib.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Nilotinib.
MibefradilThe serum concentration of Nilotinib can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Nilotinib.
MiconazoleThe serum concentration of Nilotinib can be increased when it is combined with Miconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Nilotinib.
MidazolamThe serum concentration of Nilotinib can be decreased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Nilotinib.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Nilotinib.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Nilotinib.
MinaprineThe metabolism of Minaprine can be decreased when combined with Nilotinib.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Nilotinib.
MirabegronMirabegron may increase the QTc-prolonging activities of Nilotinib.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Nilotinib.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Nilotinib.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nilotinib.
MitomycinThe serum concentration of Nilotinib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Nilotinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Nilotinib can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nilotinib.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nilotinib.
ModafinilThe serum concentration of Nilotinib can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Nilotinib.
MoexiprilMoexipril may increase the QTc-prolonging activities of Nilotinib.
MontelukastThe metabolism of Montelukast can be decreased when combined with Nilotinib.
MorphineThe metabolism of Morphine can be decreased when combined with Nilotinib.
MorphineThe serum concentration of Nilotinib can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Nilotinib.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Nilotinib.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Nilotinib.
NadololThe serum concentration of Nadolol can be increased when it is combined with Nilotinib.
NafcillinThe serum concentration of Nilotinib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nilotinib.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Nilotinib.
NaltrexoneThe serum concentration of Nilotinib can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Nilotinib.
NaringeninThe serum concentration of Nilotinib can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Nilotinib.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Nilotinib.
NefazodoneThe serum concentration of Nilotinib can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Nilotinib.
NelfinavirThe serum concentration of Nilotinib can be increased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Nilotinib.
NeostigmineThe serum concentration of Nilotinib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Nilotinib can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Nilotinib.
NevirapineThe serum concentration of Nilotinib can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Nilotinib.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Nilotinib.
NicardipineThe serum concentration of Nilotinib can be increased when it is combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Nilotinib.
NicotineThe metabolism of Nicotine can be decreased when combined with Nilotinib.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Nilotinib.
NifedipineThe serum concentration of Nilotinib can be decreased when it is combined with Nifedipine.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nilotinib.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Nilotinib.
NisoldipineThe serum concentration of Nilotinib can be increased when it is combined with Nisoldipine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Nilotinib.
NitrazepamThe serum concentration of Nilotinib can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.
NitrendipineThe serum concentration of Nilotinib can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Nilotinib.
NizatidineThe serum concentration of Nilotinib can be decreased when it is combined with Nizatidine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nilotinib.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Nilotinib.
NorethisteroneThe serum concentration of Nilotinib can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Nilotinib.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Nilotinib.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Nilotinib.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Nilotinib.
OctreotideOctreotide may increase the QTc-prolonging activities of Nilotinib.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Nilotinib.
OlanzapineThe serum concentration of Nilotinib can be decreased when it is combined with Olanzapine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nilotinib.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Nilotinib.
OlaparibThe metabolism of Nilotinib can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Nilotinib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Nilotinib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Nilotinib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nilotinib.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nilotinib.
OmeprazoleThe serum concentration of Nilotinib can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Nilotinib.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Nilotinib.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Nilotinib.
OsimertinibThe serum concentration of Nilotinib can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Nilotinib.
OuabainOuabain may decrease the cardiotoxic activities of Nilotinib.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Nilotinib.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Nilotinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Nilotinib.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nilotinib.
OxytocinOxytocin may increase the QTc-prolonging activities of Nilotinib.
P-NitrophenolThe serum concentration of Nilotinib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Nilotinib.
PaclitaxelThe serum concentration of Nilotinib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Nilotinib can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Nilotinib.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Nilotinib.
Palmitic AcidThe serum concentration of Nilotinib can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nilotinib.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Nilotinib.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Nilotinib.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Nilotinib.
PantoprazoleThe serum concentration of Nilotinib can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nilotinib.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Nilotinib.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Nilotinib.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Nilotinib.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Nilotinib.
ParoxetineThe serum concentration of Nilotinib can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Nilotinib.
PasireotidePasireotide may increase the QTc-prolonging activities of Nilotinib.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nilotinib.
PazopanibPazopanib may increase the QTc-prolonging activities of Nilotinib.
PentamidinePentamidine may increase the QTc-prolonging activities of Nilotinib.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Nilotinib.
PentobarbitalThe serum concentration of Nilotinib can be decreased when it is combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Nilotinib.
PerflutrenPerflutren may increase the QTc-prolonging activities of Nilotinib.
PergolideThe metabolism of Pergolide can be decreased when combined with Nilotinib.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nilotinib.
PerindoprilThe serum concentration of Nilotinib can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Nilotinib.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nilotinib.
PethidineThe metabolism of Pethidine can be decreased when combined with Nilotinib.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nilotinib.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Nilotinib.
PhenobarbitalThe serum concentration of Nilotinib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Nilotinib.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Nilotinib.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nilotinib.
PhenytoinThe serum concentration of Nilotinib can be decreased when it is combined with Phenytoin.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Nilotinib.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Nilotinib.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nilotinib.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Nilotinib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nilotinib.
PimozidePimozide may increase the QTc-prolonging activities of Nilotinib.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Nilotinib.
PindololThe metabolism of Pindolol can be decreased when combined with Nilotinib.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Nilotinib.
PiperazineThe metabolism of Piperazine can be decreased when combined with Nilotinib.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nilotinib.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nilotinib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nilotinib.
Platelet Activating FactorThe serum concentration of Nilotinib can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nilotinib.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Nilotinib.
PonatinibThe serum concentration of Nilotinib can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Nilotinib can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Nilotinib.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Nilotinib.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nilotinib.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Nilotinib.
PravastatinThe serum concentration of Nilotinib can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Nilotinib.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nilotinib.
PrazosinThe serum concentration of Nilotinib can be increased when it is combined with Prazosin.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Nilotinib.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Nilotinib.
PrednisoneThe serum concentration of Nilotinib can be increased when it is combined with Prednisone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Nilotinib.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Nilotinib.
PrimidoneThe serum concentration of Nilotinib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Nilotinib can be increased when it is combined with Probenecid.
ProcainamideProcainamide may increase the QTc-prolonging activities of Nilotinib.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nilotinib.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nilotinib.
ProgesteroneThe serum concentration of Nilotinib can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Nilotinib.
PromazinePromazine may increase the QTc-prolonging activities of Nilotinib.
PromazineThe metabolism of Promazine can be decreased when combined with Nilotinib.
PromethazineThe serum concentration of Nilotinib can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Nilotinib.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Nilotinib.
PropafenonePropafenone may increase the QTc-prolonging activities of Nilotinib.
PropofolThe metabolism of Propofol can be decreased when combined with Nilotinib.
PropofolPropofol may increase the QTc-prolonging activities of Nilotinib.
PropranololThe metabolism of Propranolol can be decreased when combined with Nilotinib.
PropranololThe serum concentration of Nilotinib can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Nilotinib can be increased when it is combined with Protriptyline.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Nilotinib.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nilotinib.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Nilotinib.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Nilotinib.
QuazepamThe metabolism of Quazepam can be decreased when combined with Nilotinib.
QuercetinThe serum concentration of Nilotinib can be increased when it is combined with Quercetin.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Nilotinib.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Nilotinib.
QuinacrineThe serum concentration of Nilotinib can be increased when it is combined with Quinacrine.
QuinidineQuinidine may increase the QTc-prolonging activities of Nilotinib.
QuinineQuinine may increase the QTc-prolonging activities of Nilotinib.
RabeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Nilotinib.
Rabies vaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rabies vaccine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Nilotinib.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Nilotinib.
RanitidineThe serum concentration of Nilotinib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nilotinib.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Nilotinib.
ReboxetineThe serum concentration of Nilotinib can be increased when it is combined with Reboxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Nilotinib.
RegorafenibThe serum concentration of Nilotinib can be increased when it is combined with Regorafenib.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Nilotinib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Nilotinib.
repinotanThe metabolism of repinotan can be decreased when combined with Nilotinib.
ReserpineThe serum concentration of Nilotinib can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Nilotinib.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Nilotinib.
RifabutinThe serum concentration of Nilotinib can be decreased when it is combined with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Nilotinib.
RifampicinThe serum concentration of Nilotinib can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Nilotinib.
RifapentineThe serum concentration of Nilotinib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nilotinib.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Nilotinib.
RilpivirineThe serum concentration of Nilotinib can be increased when it is combined with Rilpivirine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Nilotinib.
RiociguatThe metabolism of Riociguat can be decreased when combined with Nilotinib.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Nilotinib.
RisperidoneRisperidone may increase the QTc-prolonging activities of Nilotinib.
RitonavirThe serum concentration of Nilotinib can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Nilotinib.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Nilotinib.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nilotinib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Nilotinib.
RolapitantThe serum concentration of Nilotinib can be increased when it is combined with Rolapitant.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Nilotinib.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Nilotinib.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nilotinib.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nilotinib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nilotinib.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nilotinib.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nilotinib.
Roxatidine acetateThe serum concentration of Nilotinib can be decreased when it is combined with Roxatidine acetate.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Nilotinib.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Nilotinib.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Nilotinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Nilotinib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Nilotinib.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Nilotinib.
SaquinavirThe serum concentration of Nilotinib can be increased when it is combined with Saquinavir.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Nilotinib.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Nilotinib.
ScopolamineThe serum concentration of Nilotinib can be increased when it is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Nilotinib.
SelegilineThe serum concentration of Nilotinib can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be decreased when combined with Nilotinib.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nilotinib.
SertindoleThe metabolism of Sertindole can be decreased when combined with Nilotinib.
SertralineThe metabolism of Sertraline can be decreased when combined with Nilotinib.
SertralineThe serum concentration of Nilotinib can be increased when it is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Nilotinib.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Nilotinib.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Nilotinib.
SildenafilThe metabolism of Nilotinib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.
SiltuximabThe serum concentration of Nilotinib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nilotinib can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Nilotinib.
SimvastatinThe serum concentration of Nilotinib can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nilotinib.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Nilotinib.
SirolimusThe serum concentration of Nilotinib can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Nilotinib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nilotinib.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Nilotinib.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Nilotinib.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Nilotinib.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Nilotinib.
SorafenibThe serum concentration of Nilotinib can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Nilotinib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nilotinib.
SparteineThe metabolism of Sparteine can be decreased when combined with Nilotinib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nilotinib.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Nilotinib.
SpironolactoneThe serum concentration of Nilotinib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Nilotinib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Nilotinib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Nilotinib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Nilotinib can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Nilotinib.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nilotinib.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nilotinib.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Nilotinib.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nilotinib.
SulfinpyrazoneThe serum concentration of Nilotinib can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Nilotinib.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nilotinib.
SumatriptanThe serum concentration of Nilotinib can be increased when it is combined with Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Nilotinib.
SunitinibThe serum concentration of Nilotinib can be increased when it is combined with Sunitinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Nilotinib.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nilotinib.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nilotinib.
TacrineThe serum concentration of Nilotinib can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Nilotinib.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nilotinib.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Nilotinib.
TAK-390MRThe serum concentration of Nilotinib can be decreased when it is combined with TAK-390MR.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Nilotinib.
TamoxifenThe serum concentration of Nilotinib can be decreased when it is combined with Tamoxifen.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Nilotinib.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Nilotinib.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Nilotinib.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nilotinib.
Taurocholic AcidThe serum concentration of Nilotinib can be increased when it is combined with Taurocholic Acid.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Nilotinib.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nilotinib.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Nilotinib.
TelaprevirThe serum concentration of Nilotinib can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Nilotinib.
TelavancinTelavancin may increase the QTc-prolonging activities of Nilotinib.
TelithromycinThe serum concentration of Nilotinib can be increased when it is combined with Telithromycin.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Nilotinib.
TelmisartanThe serum concentration of Nilotinib can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Nilotinib.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.
TemsirolimusThe serum concentration of Nilotinib can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Nilotinib.
TerazosinThe serum concentration of Nilotinib can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nilotinib.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Nilotinib.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nilotinib.
TerfenadineThe serum concentration of Nilotinib can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Nilotinib can be increased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nilotinib.
TesmilifeneThe serum concentration of Nilotinib can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nilotinib.
TestosteroneThe serum concentration of Nilotinib can be increased when it is combined with Testosterone.
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Nilotinib.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Nilotinib.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nilotinib.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nilotinib.
ThioridazineThioridazine may increase the QTc-prolonging activities of Nilotinib.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Nilotinib.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Nilotinib.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Nilotinib.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Nilotinib.
TicagrelorThe serum concentration of Nilotinib can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Nilotinib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Nilotinib.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Nilotinib.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nilotinib.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Nilotinib.
TizanidineTizanidine may increase the QTc-prolonging activities of Nilotinib.
TocilizumabThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.
TofacitinibNilotinib may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nilotinib.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Nilotinib.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Nilotinib.
TolterodineTolterodine may increase the QTc-prolonging activities of Nilotinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nilotinib.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nilotinib.
TorasemideThe metabolism of Torasemide can be decreased when combined with Nilotinib.
ToremifeneToremifene may increase the QTc-prolonging activities of Nilotinib.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Nilotinib.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nilotinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Nilotinib.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Nilotinib.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Nilotinib.
TrazodoneThe serum concentration of Nilotinib can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Nilotinib.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nilotinib.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Nilotinib.
TriazolamThe metabolism of Triazolam can be decreased when combined with Nilotinib.
TrifluoperazineThe serum concentration of Nilotinib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Nilotinib can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nilotinib.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nilotinib.
TrimethoprimThe serum concentration of Nilotinib can be decreased when it is combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Nilotinib.
TrimipramineThe serum concentration of Nilotinib can be increased when it is combined with Trimipramine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Nilotinib.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Nilotinib.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Nilotinib.
TroleandomycinThe serum concentration of Nilotinib can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Nilotinib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nilotinib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nilotinib.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nilotinib.
VandetanibNilotinib may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Nilotinib.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Nilotinib.
VardenafilVardenafil may increase the QTc-prolonging activities of Nilotinib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nilotinib.
VemurafenibNilotinib may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Nilotinib can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Nilotinib can be decreased when combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nilotinib.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Nilotinib.
VilanterolVilanterol may increase the QTc-prolonging activities of Nilotinib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nilotinib.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nilotinib.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Nilotinib.
VinblastineThe serum concentration of Nilotinib can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nilotinib.
VincristineThe serum concentration of Nilotinib can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Nilotinib.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nilotinib.
VinorelbineThe serum concentration of Nilotinib can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nilotinib.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Nilotinib.
VoriconazoleThe serum concentration of Nilotinib can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Nilotinib.
VorinostatVorinostat may increase the QTc-prolonging activities of Nilotinib.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nilotinib.
WarfarinThe metabolism of Warfarin can be decreased when combined with Nilotinib.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Nilotinib.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nilotinib.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nilotinib.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Nilotinib.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nilotinib.
ZileutonThe metabolism of Zileuton can be decreased when combined with Nilotinib.
ZimelidineThe serum concentration of Nilotinib can be increased when it is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Nilotinib.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nilotinib.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Nilotinib.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Nilotinib.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Nilotinib.
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Nilotinib.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Syntaxin binding
Specific Function:
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 ...
Gene Name:
ABL1
Uniprot ID:
P00519
Molecular Weight:
122871.435 Da
References
  1. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. [PubMed:17929114 ]
  2. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [PubMed:17715389 ]
  3. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19;94(12):1765-9. Epub 2006 May 23. [PubMed:16721371 ]
  4. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F: Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009 Sep 21;3:89-101. [PubMed:19920925 ]
  5. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M: Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. [PubMed:19822896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007 Aug 15;13(16):4874-81. [PubMed:17699867 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H: Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2011 Jan;51(1):75-83. doi: 10.1177/0091270010367428. Epub 2010 Aug 11. [PubMed:20702754 ]
  2. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
  3. Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H: Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015. [PubMed:20110053 ]
  4. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
  2. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H: Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig. 2011;31(3):169-79. doi: 10.2165/11538700-000000000-00000. [PubMed:21184622 ]
  2. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
  2. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662 ]
  3. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 03:39 / Updated on September 26, 2016 02:13